Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s disease

12 Apr 2017

Abstract excerpt

Memory loss characterizes several neurodegenerative disorders, including Alzheimer's disease (AD). Inhibition of type 4 phosphodiesterase (PDE4) and elevation of cyclic adenosine monophosphate (cAMP) has emerged as a promising therapeutic approach to treat cognitive deficits. However, PDE4 exists in several isoforms and pan inhibitors cannot be used in humans due to severe emesis. Here, we present GEBR-32a, a new...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholinesterase and Neurodegenerative Diseases
Share to Phosphodiesterase function and regulation
Share to Receptor Mechanisms and Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28402318
DOI: 10.1038/srep46320

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s diseasePMID 28402318Read ↗

In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophreniaSemantic proximity Read ↗

Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer’s diseaseSemantic proximity Read ↗

Changes in PDE4D Isoforms in the Hippocampus of a Patient With Advanced Alzheimer DiseaseSemantic proximity Read ↗

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's diseaseSemantic proximity Read ↗

A Novel multifunctional 5,6-dimethoxy-indanone-chalcone-carbamate hybrids alleviates cognitive decline in Alzheimer’s disease by dual inhibition of acetylcholinesterase and inflammationSemantic proximity Read ↗

Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.Semantic proximity Read ↗

Inhibition of phosphodiesterase 4B as a novel therapeutic strategy for the treatment of refractory epilepsySemantic proximity Read ↗

Discovery of in Vivo Chemical Probes for Treating Alzheimer’s Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective InhibitorsSemantic proximity Read ↗

Phosphodiesterases in neurodegenerative disordersSemantic proximity Read ↗

Dehydroevodiamine•HCl Protects Against Memory Impairment and Cerebral Amyloid-β Production in Tg2576 Mice by Acting as a β-Secretase Inhibitor.Semantic proximity Read ↗

Cyclic nucleotide signalling: a molecular approach to drug discovery for Alzheimer's diseaseSemantic proximity Read ↗

Phosphodiesterase 4B: Master Regulator of Brain SignalingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.